Supplementary Figure 15: Comparisons of the spectrum of cancer diagnoses for ULSAM participants with and without LOY who were successfully genotyped on Illumina BeadChips and scored for structural genetic variants.

The cutoff level for LOY used for these comparisons was mLRR-Y <–0.139, corresponding to LOY in >18% of cells (see Fig. 2, Supplementary Fig. 3 and the text). Panels a and b display cancer diagnoses for the entire cohort of 1,153 men with 93 participants scored with LOY and 1,060 subjects who were not scored with LOY, respectively. Panels c and d show the distribution of the cancer diagnoses in the cohort after excluding subjects with cancer before blood sampling. In the remaining 982 men, 80 subjects were scored with LOY and 902 subjects were not scored with LOY. All cancer diagnoses were grouped into 13 categories, and, for each category, the percentage of cases is shown, followed by the absolute number of patients (in parentheses) with the diagnosis category. GI, gastrointestinal; ENT, ear/nose/throat; CNS, central nervous system.